

# Alberto M Pereira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2967088/publications.pdf>

Version: 2024-02-01

331  
papers

17,159  
citations

13099  
68  
h-index

22166  
113  
g-index

339  
all docs

339  
docs citations

339  
times ranked

11249  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low sclerostin levels after long-term remission of acromegaly. <i>Endocrine</i> , 2022, 75, 228-238.	2.3	2
2	Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly. <i>Pituitary</i> , 2022, 25, 229-237.	2.9	3
3	Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study. <i>Pituitary</i> , 2022, 25, 308-320.	2.9	4
4	Towards a pituitary apoplexy classification based on clinical presentation and patient journey. <i>Endocrine</i> , 2022, 76, 132-141.	2.3	4
5	ENDO-ERN ON RARE ENDOCRINE CONDITIONS: Endo-ERN in its fifth year: a pinch of care, science, curiosity and new horizons. <i>Endocrine Connections</i> , 2022, 11, .	1.9	1
6	Gene expression changes in the brain of a Cushing's syndrome mouse model. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13124.	2.6	8
7	State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1225-1238.	3.6	9
8	Long-term effects of glucocorticoid excess on the brain. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	23
9	Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 178.	2.7	8
10	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. <i>Pituitary</i> , 2022, 25, 587-601.	2.9	9
11	Clinical and radiographic assessment of peripheral joints in controlled acromegaly. <i>Pituitary</i> , 2022, 25, 622-635.	2.9	5
12	Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 188-200.	3.6	17
13	Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 577-587.	3.6	19
14	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. <i>Pituitary</i> , 2021, 24, 334-350.	2.9	21
15	Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. <i>Pituitary</i> , 2021, 24, 79-95.	2.9	5
16	Postoperative endocrinological follow-up. , 2021, , 439-446.		0
17	Variants of FOXO3 and RPA3 genes affecting IGF-1 levels alter the risk of development of primary osteoarthritis. <i>European Journal of Endocrinology</i> , 2021, 184, 29-39.	3.7	6
18	Educational and knowledge gaps within the European reference network on rare endocrine conditions. <i>Endocrine Connections</i> , 2021, 10, 37-44.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Introduction to Endo-ERN's scope and mission. <i>Endocrine</i> , 2021, 71, 537-538.	2.3	7
20	Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. <i>Endocrine</i> , 2021, 71, 561-568.	2.3	4
21	Effects of Long-Term Endogenous Corticosteroid Exposure on Brain Volume and Glial Cells in the AdKO Mouse. <i>Frontiers in Neuroscience</i> , 2021, 15, 604103.	2.8	24
22	Conditioning cortisol in healthy young women – A randomized controlled trial. <i>Psychoneuroendocrinology</i> , 2021, 124, 105081.	2.7	5
23	Central serous chorioretinopathy in active endogenous Cushing's syndrome. <i>Scientific Reports</i> , 2021, 11, 2748.	3.3	10
24	Access to patient oriented information – a baseline Endo-ERN survey among patients with rare endocrine disorders. <i>Endocrine</i> , 2021, 71, 542-548.	2.3	3
25	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.2	31
26	CPMS – improving patient care in Europe via virtual case discussions. <i>Endocrine</i> , 2021, 71, 549-554.	2.3	13
27	Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3300-e3311.	3.6	7
28	European Reference Networks: challenges and opportunities. <i>Journal of Community Genetics</i> , 2021, 12, 217-229.	1.2	21
29	Serum Inflammation-based Scores in Endocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3796-e3819.	3.6	19
30	Adrenal Vein Sampling in a Patient With Primary Hyperaldosteronism and Severe Contrast Allergy. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab122.	0.2	4
31	SALIVARY ALPHA-AMYLASE LEVELS MAY CORRELATE WITH CENTRAL SEROUS CHORIORETINOPATHY ACTIVITY. <i>Retina</i> , 2021, 41, 2479-2484.	1.7	8
32	Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient's Perspective. <i>Frontiers in Endocrinology</i> , 2021, 12, 701365.	3.5	8
33	The PRolaCT studies – a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. <i>Trials</i> , 2021, 22, 653.	1.6	7
34	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in female mice. <i>Aging Cell</i> , 2021, 20, e13474.	6.7	9
35	Potential associations between immune signaling genes, deactivated microglia, and oligodendrocytes and cortical gray matter loss in patients with long-term remitted Cushing's disease. <i>Psychoneuroendocrinology</i> , 2021, 132, 105334.	2.7	6
36	Postoperative diabetes insipidus: how to define and grade this complication?. <i>Pituitary</i> , 2021, 24, 284-291.	2.9	50

#	ARTICLE	IF	CITATIONS
37	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
38	Hypophysitis: A comprehensive overview. <i>Presse Medicale</i> , 2021, 50, 104076.	1.9	7
39	The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone. <i>BMJ Open</i> , 2021, 11, e054405.	1.9	3
40	Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1020-1029.	3.6	66
41	Early postoperative HPA-axis testing after pituitary tumor surgery: reliability and safety of basal cortisol and CRH test. <i>Endocrine</i> , 2020, 67, 161-171.	2.3	14
42	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207
43	Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e32-e41.	3.6	78
44	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e70-e84.	3.6	22
45	Hair cortisol concentrations in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2020, 98, 390-395.	1.1	5
46	SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements. <i>Endocrine</i> , 2020, 70, 123-133.	2.3	10
47	The EuRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8743.	2.6	13
48	Endoscopic Surgery for Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 487-503.	3.2	17
49	SUN-070 European Registries for Rare Endocrine Conditions (EuRECa): Results from the Platform for E-reporting of Rare Endocrine Conditions (e-REC). <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
50	Cortical thickness abnormalities in long-term remitted Cushing's disease. <i>Translational Psychiatry</i> , 2020, 10, 293.	4.8	12
51	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	5.7	183
52	The epidemiology of aggressive pituitary tumors (and its challenges). <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 209-212.	5.7	38
53	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery. <i>Endocrine</i> , 2020, 69, 175-187.	2.3	18
54	Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. <i>Pituitary</i> , 2020, 23, 417-429.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Response to Letter to the Editor: "Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis" Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3040-e3041.	3.6	4
56	Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2020, 15, 144.	2.7	15
57	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. Journal of Internal Medicine, 2020, 288, 168-182.	6.0	35
58	Response to Letter to the Editor: "IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction" Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2315-e2316.	3.6	0
59	Glucocorticoid Sexual Dimorphism in Metabolism: Dissecting the Role of Sex Hormones. Trends in Endocrinology and Metabolism, 2020, 31, 357-367.	7.1	32
60	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. Lancet Diabetes and Endocrinology, 2020, 8, 348.	11.4	1
61	Decreased Aerobic Exercise Capacity After Long-Term Remission From Cushing Syndrome: Exploration of Mechanisms. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1408-e1418.	3.6	6
62	Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. Journal of Bone and Mineral Research, 2020, 36, 1729-1738.	2.8	23
63	68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. European Journal of Hybrid Imaging, 2020, 4, 4.	1.5	5
64	Peptide hormone analysis in diagnosis and treatment of Differences of Sex Development: joint position paper of EU COST Action "DSDnet" and European Reference Network on Rare Endocrine Conditions. European Journal of Endocrinology, 2020, 182, P1-P15.	3.7	20
65	An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. European Journal of Endocrinology, 2020, 183, 141-148.	3.7	9
66	Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. European Journal of Endocrinology, 2020, 183, 427-437.	3.7	24
67	Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5325-5337.	3.6	27
68	Sex Differences in Presentation but Not in Outcome for ACTH-Dependent Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 580.	3.5	13
69	Acromegaly. Nature Reviews Disease Primers, 2019, 5, 20.	30.5	247
70	Healthcare utilization and costs among patients with non-functioning pituitary adenomas. Endocrine, 2019, 64, 330-340.	2.3	9
71	Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing's disease: surgical outcome, mortality, and complications. Orphanet Journal of Rare Diseases, 2019, 14, 64.	2.7	24
72	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. Acta Ophthalmologica, 2019, 97, e572-e579.	1.1	18

#	ARTICLE	IF	CITATIONS
73	The partner's perspective of the impact of pituitary disease: Looking beyond the patient. Journal of Health Psychology, 2019, 24, 1687-1697.	2.3	19
74	The current landscape of European registries for rare endocrine conditions. European Journal of Endocrinology, 2019, 180, 89-98.	3.7	25
75	The incidence of adrenal crisis in the postoperative period of HPA axis insufficiency after surgical treatment for Cushing's syndrome. European Journal of Endocrinology, 2019, 181, 201-210.	3.7	14
76	Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care. European Journal of Endocrinology, 2019, 181, 375-387.	3.7	19
77	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	3.7	53
78	Three percent annually on systemic glucocorticoids: facts, worries and perspectives. European Journal of Endocrinology, 2019, 181, C23-C28.	3.7	6
79	Effects of Glucocorticoids on the Brain. , 2019, , 360-368.		0
80	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	3.7	37
81	How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. Pituitary, 2018, 21, 208-216.	2.9	29
82	How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary, 2018, 21, 310-322.	2.9	19
83	Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. Pituitary, 2018, 21, 84-97.	2.9	84
84	Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors. Chronobiology International, 2018, 35, 368-377.	2.0	5
85	Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice. Endocrinology, 2018, 159, 3925-3936.	2.8	27
86	Work disability and its determinants in patients with pituitary tumor-related disease. Pituitary, 2018, 21, 593-604.	2.9	31
87	Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis. Pituitary, 2018, 21, 524-534.	2.9	71
88	Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. Pituitary, 2018, 21, 631-641.	2.9	61
89	Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement. Endocrine, 2018, 62, 136-143.	2.3	49
90	Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. Frontiers in Endocrinology, 2018, 9, 39.	3.5	22

#	ARTICLE	IF	CITATIONS
91	Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 176, 339-347.	3.7	51
92	The phenotype of SDHB germline mutation carriers: a nationwide study. <i>European Journal of Endocrinology</i> , 2017, 177, 115-125.	3.7	38
93	Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2017, 177, 59-72.	3.7	38
94	Acromegalic arthropathy in various stages of the disease: an MRI study. <i>European Journal of Endocrinology</i> , 2017, 176, 779-790.	3.7	18
95	Glucocorticoid Regulation of Neurocognitive and Neuropsychiatric Function. , 2017, , 27-41.		0
96	Corticosteroid use and mortality risk in patients with perforated colonic diverticular disease: a population-based cohort study. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000136.	2.7	14
97	A Patient (46XX) With Congenital Adrenal Hyperplasia and Prostate Cancer: A Case Report. <i>Journal of the Endocrine Society</i> , 2017, 1, 1213-1216.	0.2	7
98	Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. <i>Frontiers in Endocrinology</i> , 2017, 8, 40.	3.5	63
99	Characteristics and Mortality of Pneumocystis Pneumonia in Patients With Cushing's Syndrome: A Plea for Timely Initiation of Chemoprophylaxis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx002.	0.9	18
100	Cataplexy in a patient treated for prolactinoma: Case report. <i>Vojnosanitetski Pregled</i> , 2017, 74, 782-785.	0.2	1
101	Primary hypercortisolism and pheochromocytoma next to, but not related to, each other. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213359.	0.5	0
102	Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome. <i>European Journal of Ophthalmology</i> , 2016, 26, 442-448.	1.3	27
103	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. <i>PLoS ONE</i> , 2016, 11, e0152390.	2.5	3
104	DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R247-R253.	3.7	21
105	Intraoperative Identification of a Normal Pituitary Gland and an Adenoma Using Near-Infrared Fluorescence Imaging and Low-Dose Indocyanine Green. <i>Operative Neurosurgery</i> , 2016, 12, 260-268.	0.8	20
106	Pituitary Hormone Secretion Profiles in IGSF1 Deficiency Syndrome. <i>Neuroendocrinology</i> , 2016, 103, 408-416.	2.5	22
107	IGSF1 Deficiency: Lessons From an Extensive Case Series and Recommendations for Clinical Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1627-1636.	3.6	68
108	Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2675-2682.	3.6	8



#	ARTICLE	IF	CITATIONS
109	Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation. British Journal of Pharmacology, 2016, 173, 1793-1804.	5.4	35
110	Vascular Health in Patients in Remission of Cushing's Syndrome Is Comparable With That in BMI-Matched Controls. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4142-4150.	3.6	12
111	Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels. Psychoneuroendocrinology, 2016, 72, 80-86.	2.7	15
112	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes and Endocrinology, the, 2016, 4, 569-576.	11.4	151
113	Mild deficits in attentional control in patients with the <sc>IGSF</sc>1 deficiency syndrome. Clinical Endocrinology, 2016, 84, 896-903.	2.4	20
114	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. European Journal of Endocrinology, 2016, 174, 651-662.	3.7	40
115	The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary, 2016, 19, 293-302.	2.9	30
116	Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature. European Journal of Endocrinology, 2016, 174, 705-716.	3.7	9
117	Mild cognitive deficits in patients with primary adrenal insufficiency. Psychoneuroendocrinology, 2016, 63, 170-177.	2.7	24
118	Mild cognitive deficits in patients on stable treatment for primary adrenal insufficiency. Psychoneuroendocrinology, 2015, 61, 46.	2.7	2
119	Neuropsychological functioning in acromegaly: towards identification of modifiable factors to improve long-term care after remission. Endocrine, 2015, 50, 523-525.	2.3	2
120	Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. European Journal of Endocrinology, 2015, 172, 583-593.	3.7	21
121	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology, 2015, 173, R1-R14.	3.7	141
122	Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2456-2462.	3.6	21
123	Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary, 2015, 18, 752-776.	2.9	95
124	Resting-State Functional Connectivity in Patients with Long-Term Remission of Cushing's Disease. Neuropsychopharmacology, 2015, 40, 1888-1898.	5.4	44
125	STAT5B mutations in heterozygous state have negative impact on height: another clue in human stature heritability. European Journal of Endocrinology, 2015, 173, 291-296.	3.7	29
126	Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. European Journal of Endocrinology, 2015, 173, 37-42.	3.7	5



#	ARTICLE	IF	CITATIONS
127	MANAGEMENT OF ENDOCRINE DISEASE: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2015, 172, R143-R149.	3.7	80
128	Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2171-2180.	3.6	304
129	Outcome of complications in acromegaly patients after long-term disease remission. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 499-510.	2.4	4
130	Hypothalamicâ€Pituitaryâ€Adrenal Axis Functioning in Huntington's Disease and its Association with Depressive Symptoms and Suicidality. <i>Journal of Neuroendocrinology</i> , 2015, 27, 234-244.	2.6	32
131	Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. <i>European Journal of Endocrinology</i> , 2015, 173, 269-273.	3.7	23
132	More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. <i>Growth Hormone and IGF Research</i> , 2015, 25, 219-226.	1.1	19
133	Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3288-3296.	3.6	116
134	Altered neural processing of emotional faces in remitted Cushing's disease. <i>Psychoneuroendocrinology</i> , 2015, 59, 134-146.	2.7	40
135	Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. <i>Pituitary</i> , 2015, 18, 86-100.	2.9	51
136	Response to the Letter by Lindholm, et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L66-L67.	3.6	0
137	High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma. <i>PLoS ONE</i> , 2014, 9, e90602.	2.5	15
138	Determinants of Altered Sleep-Wake Rhythmicity in Patients Treated for Nonfunctioning Pituitary Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4497-4505.	3.6	23
139	Hormone Secretion by Pituitary Adenomas Is Characterized by Increased Disorderliness and Spikiness but More Regular Pulsing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3836-3844.	3.6	9
140	Effects of up to 15 years of recombinant human <sc>GH</sc> (rh<sc>GH</sc>) replacement on bone metabolism in adults with Growth Hormone Deficiency (<sc>GHD</sc>): The Leiden Cohort Study. <i>Clinical Endocrinology</i> , 2014, 81, 727-735.	2.4	29
141	Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. <i>Radiotherapy and Oncology</i> , 2014, 113, 102-107.	0.6	29
142	A longâ€term followâ€up study of eighteen patients with thyrotrophinâ€secreting pituitary adenomas. <i>Clinical Endocrinology</i> , 2014, 80, 395-402.	2.4	52
143	Patients With Adrenal Insufficiency Hate Their Medication: Concerns and Stronger Beliefs About the Necessity of Hydrocortisone Intake Are Associated With More Negative Illness Perceptions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3668-3676.	3.6	27
144	Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. <i>European Journal of Endocrinology</i> , 2014, 170, 181-191.	3.7	19

#	ARTICLE	IF	CITATIONS
145	Impact of Adiposity and Fat Distribution on the Dynamics of Adrenocorticotropin and Cortisol Rhythms. <i>Current Obesity Reports</i> , 2014, 3, 387-395.	8.4	9
146	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. <i>European Journal of Endocrinology</i> , 2014, 171, 217-228.	3.7	33
147	Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. <i>European Journal of Endocrinology</i> , 2014, 170, 263-272.	3.7	7
148	Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. <i>Pituitary</i> , 2014, 17, 44-52.	2.9	25
149	Thyrotropin Secretion in Healthy Subjects Is Robust and Independent of Age and Gender, and Only Weakly Dependent on Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 570-578.	3.6	28
150	Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. <i>European Journal of Endocrinology</i> , 2014, 171, 171-182.	3.7	61
151	Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and symptomatic osteoarthritis in women. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 433-436.	0.9	5
152	Copy number variants in patients with short stature. <i>European Journal of Human Genetics</i> , 2014, 22, 602-609.	2.8	60
153	Long-term effects of treatment of pituitary adenomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 124, 361-371.	1.8	7
154	Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 659-667.	2.7	76
155	D05 Hypothalamic-pituitary-adrenal Axis Activity in Huntington's Disease And Its Association With Depressive Symptoms And Suicidality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A33-A33.	1.9	0
156	Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease. <i>Pituitary</i> , 2013, 16, 536-544.	2.9	26
157	An Activating Mutation in the Kinase Homology Domain of the Natriuretic Peptide Receptor-2 Causes Extremely Tall Stature Without Skeletal Deformities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1988-E1998.	3.6	78
158	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4942-4952.	3.6	81
159	Loss-of-function mutations in the immunoglobulin superfamily member 1 gene (IGSF1) cause a novel, X-linked syndrome of central hypothyroidism and testicular enlargement. <i>Lancet, The</i> , 2013, 381, S15.	13.7	0
160	Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). <i>Growth Hormone and IGF Research</i> , 2013, 23, 159-164.	1.1	14
161	Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2277-2284.	3.6	324
162	Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study. <i>European Journal of Endocrinology</i> , 2013, 169, 811-819.	3.7	84

#	ARTICLE	IF	CITATIONS
163	Relationship between left ventricular diastolic function and arterial stiffness in asymptomatic patients with diabetes mellitus. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 609-616.	1.5	19
164	Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 352-361.	3.6	57
165	Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4808-4815.	3.6	90
166	Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. <i>European Journal of Endocrinology</i> , 2013, 169, R1-R14.	3.7	74
167	Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1880-E1890.	3.6	44
168	Non-invasive assessment of microcirculation by sidestream dark field imaging as a marker of coronary artery disease in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 123-134.	2.0	26
169	Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet. <i>Physiological Reports</i> , 2013, 1, e00103.	1.7	12
170	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. <i>PLoS ONE</i> , 2013, 8, e63882.	2.5	14
171	Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 27-34.	3.7	62
172	Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. <i>European Journal of Endocrinology</i> , 2012, 167, 235-244.	3.7	46
173	MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects. <i>European Journal of Endocrinology</i> , 2012, 167, 311-326.	3.7	226
174	The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1303-1310.	3.6	92
175	Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. <i>European Journal of Endocrinology</i> , 2012, 166, 407-413.	3.7	19
176	Genetic Analysis of Short Children with Apparent Growth Hormone Insensitivity. <i>Hormone Research in Paediatrics</i> , 2012, 77, 320-333.	1.8	45
177	The use of an early postoperative CRH test to assess adrenal function after transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2012, 15, 436-444.	2.9	12
178	Treatment of nonfunctioning pituitary adenomas: What were the contributions of the last 10years? A critical view. <i>Annales D'Endocrinologie</i> , 2012, 73, 111-116.	1.4	20
179	Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. <i>Nature Genetics</i> , 2012, 44, 1375-1381.	21.4	169
180	Drawings Reflect a New Dimension of the Psychological Impact of Long-Term Remission of Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3123-3131.	3.6	32

#	ARTICLE	IF	CITATIONS
181	The effects of high fat diet on the basal activity of the hypothalamusâ€“pituitaryâ€“adrenal axis in mice. <i>Journal of Endocrinology</i> , 2012, 214, 191-197.	2.6	48
182	Relationship between insulin-like growth factor-1 and radiographic disease in patients with primary osteoarthritis: a systematic review. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 79-86.	1.3	19
183	Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2â€“year followâ€“up study. <i>Clinical Endocrinology</i> , 2012, 77, 99-105.	2.4	54
184	Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. <i>Pituitary</i> , 2012, 15, 71-83.	2.9	274
185	Cognitive impairment and psychopathology in patients with pituitary diseases. <i>Netherlands Journal of Medicine</i> , 2012, 70, 255-60.	0.5	20
186	Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 264-268.	2.3	17
187	Relationship between vascular stiffness and stress myocardial perfusion imaging in asymptomatic patients with diabetes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2050-2057.	6.4	10
188	Low Incidence of Adrenal Insufficiency after Transsphenoidal Surgery in Patients with Acromegaly: A Long-Term Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1163-E1170.	3.6	17
189	Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3525-3532.	3.6	161
190	Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1524-1532.	3.6	50
191	Pituitary Dysfunction in Adult Patients after Cranial Radiotherapy: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2330-2340.	3.6	126
192	Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2912-2920.	3.6	131
193	Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3550-3558.	3.6	69
194	Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 527-535.	3.7	77
195	Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. <i>European Journal of Endocrinology</i> , 2011, 165, 225-231.	3.7	59
196	Effects of High Fat Diet on the Basal Activity of the Hypothalamus-Pituitary-Adrenal Axis in Mice: A Systematic Review. <i>Hormone and Metabolic Research</i> , 2011, 43, 899-906.	1.5	23
197	Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 320-325.	0.9	43
198	Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2011, 164, 83-87.	3.7	16

#	ARTICLE	IF	CITATIONS
199	GH replacement therapy in elderly GH-deficient patients: a systematic review. European Journal of Endocrinology, 2011, 164, 657-665.	3.7	50
200	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 2011, 165, 383-392.	3.7	322
201	Coping Strategies in Patients after Treatment for Functioning or Nonfunctioning Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 964-971.	3.6	67
202	High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. European Journal of Endocrinology, 2011, 164, 475-483.	3.7	125
203	Manifesto for the current understanding and management of traumatic brain injury-induced hypopituitarism. Journal of Endocrinological Investigation, 2011, 34, 541-3.	3.3	17
204	Endocriene tumoren. , 2011, , 513-555.		0
205	The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. Journal of Bone and Mineral Research, 2010, 25, 1385-1391.	2.8	40
206	Neuropsychiatric Disorders in Cushing's Syndrome. Neuroendocrinology, 2010, 92, 65-70.	2.5	125
207	Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging. European Journal of Endocrinology, 2010, 163, 435-441.	3.7	25
208	Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. European Journal of Endocrinology, 2010, 162, 331-340.	3.7	87
209	Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease. New England Journal of Medicine, 2010, 362, 1846-1848.	27.0	233
210	Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. European Journal of Endocrinology, 2010, 162, 11-18.	3.7	112
211	Cortisol Production Rate Is Similarly Elevated in Obese Women with or without the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3318-3324.	3.6	20
212	Increased Prevalence of Psychopathology and Maladaptive Personality Traits after Long-Term Cure of Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E129-E141.	3.6	121
213	Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, In Patients after Long-Term Cure of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E392-E402.	3.6	63
214	Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3758-3762.	3.6	100
215	Thyrotropin Secretion in Mild and Severe Primary Hypothyroidism Is Distinguished by Amplified Burst Mass and Basal Secretion with Increased Spikiness and Approximate Entropy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 928-934.	3.6	37
216	Association of the M1V<i>PRKAR1A</i> Mutation with Primary Pigmented Nodular Adrenocortical Disease in Two Large Families. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 338-342.	3.6	34

#	ARTICLE	IF	CITATIONS
217	Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 43-51.	3.6	198
218	Acromegaly Is Associated with an Increased Prevalence of Colonic Diverticula: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2073-2079.	3.6	46
219	Subtle Cognitive Impairments in Patients with Long-Term Cure of Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2699-2714.	3.6	140
220	Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Hormone and IGF Research, 2010, 20, 226-233.	1.1	54
221	Body Surface Area Determines the Cortisol Production Rate in Obese Patients with Polycystic Ovary Syndrome and Obese Healthy Women.. , 2010, , P2-404-P2-404.		0
222	Trauma Severity, but Not Hypopituitarism, Affects Cognitive Function after Traumatic Brain Injury: A Multi-Center Study in the Netherlands.. , 2010, , P1-260-P1-260.		0
223	Update in prolactinomas. Netherlands Journal of Medicine, 2010, 68, 104-12.	0.5	36
224	Lanreotide Autogel® in the Treatment of Acromegaly. Clinical Medicine Therapeutics, 2009, 1, CMT.S2150.	0.1	0
225	Cost-effectiveness of lanreotide Autogel® in treatment algorithms of acromegaly. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 223-234.	1.4	27
226	Endothelial Dysfunction in Diabetic Patients with Abnormal Myocardial Perfusion in the Absence of Epicardial Obstructive Coronary Artery Disease. Journal of Nuclear Medicine, 2009, 50, 1980-1986.	5.0	16
227	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology, 2009, 161, 923-931.	3.7	223
228	The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4671-4678.	3.6	33
229	Differences in Atherosclerotic Plaque Burden and Morphology Between Type 1 and 2 Diabetes as Assessed by Multislice Computed Tomography. Diabetes Care, 2009, 32, 1507-1512.	8.6	43
230	Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing's syndrome. European Journal of Endocrinology, 2009, 161, 695-703.	3.7	33
231	Pretreatment Insulin-Like Growth Factor-I Concentrations Predict Radiographic Osteoarthritis in Acromegalic Patients with Long-Term Cured Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2374-2379.	3.6	32
232	Thyrotropin Secretion Profiles Are Not Different in Men and Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3964-3967.	3.6	50
233	Disordered and Increased Adrenocorticotropin Secretion with Diminished Adrenocorticotropin Potency in Obese in Premenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2991-2997.	3.6	14
234	Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3721-3730.	3.6	90



#	ARTICLE	IF	CITATIONS
235	Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. <i>European Journal of Endocrinology</i> , 2009, 160, 631-638.	3.7	23
236	Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1118-1124.	3.6	109
237	High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a caseâ€”control study. <i>European Journal of Endocrinology</i> , 2009, 160, 357-365.	3.7	70
238	Usefulness of Carotid Intima-Media Thickness in Patients With Diabetes Mellitus as a Predictor of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 104, 1041-1046.	1.6	27
239	Pituitary-hormone secretion by thyrotropinomas. <i>Pituitary</i> , 2009, 12, 200-210.	2.9	14
240	Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. <i>Pituitary</i> , 2009, 12, 339-346.	2.9	39
241	Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. <i>European Journal of Internal Medicine</i> , 2009, 20, 387-393.	2.2	25
242	ACTH-producing pheochromocytoma: Clinical considerations and concise review of the literature. <i>European Journal of Internal Medicine</i> , 2009, 20, 682-685.	2.2	46
243	Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. <i>Diabetologia</i> , 2008, 51, 1581-1593.	6.3	60
244	Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2008, 68, 605-609.	2.4	27
245	Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. <i>Clinical Endocrinology</i> , 2008, 69, 123-128.	2.4	65
246	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. <i>Clinical Endocrinology</i> , 2008, 69, 769-774.	2.4	33
247	Diseaseâ€”specific impairments in quality of life during longâ€”term followâ€”up of patients with different pituitary adenomas. <i>Clinical Endocrinology</i> , 2008, 69, 775-784.	2.4	148
248	Somatostatin analog treatment is associated with an increased sleep latency in patients with long-term biochemical remission of acromegaly. <i>Growth Hormone and IGF Research</i> , 2008, 18, 446-453.	1.1	10
249	The role of pegvisomant in the treatment of acromegaly. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 691-704.	3.1	9
250	Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. <i>European Journal of Endocrinology</i> , 2008, 159, 363-367.	3.7	71
251	Rituximab in relapsing Graves' disease, a phase II study. <i>European Journal of Endocrinology</i> , 2008, 159, 609-615.	3.7	86
252	Mortality in Acromegaly: A Metaanalysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 61-67.	3.6	464



#	ARTICLE	IF	CITATIONS
253	Treatment and Follow-Up of Clinically Nonfunctioning Pituitary Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3717-3726.	3.6	216
254	Recombinant human GH replacement increases CD34+ cells and improves endothelial function in adults with GH deficiency. <i>European Journal of Endocrinology</i> , 2008, 159, 105-111.	3.7	17
255	Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls. <i>European Journal of Endocrinology</i> , 2008, 159, 705-712.	3.7	10
256	Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3348-3356.	3.6	128
257	Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2828-2834.	3.6	49
258	Thyrotropin Secretion by Thyrotropinomas Is Characterized by Increased Pulse Frequency, Delayed Diurnal Rhythm, Enhanced Basal Secretion, Spikiness, and Disorderliness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4052-4057.	3.6	29
259	Height Gain with Combined Growth Hormone and Gonadotropin-Releasing Hormone Analog Therapy in Two Pubertal Siblings with a Growth Hormone-Releasing Hormone Receptor Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 204-207.	3.6	6
260	Increased aortic root diameters in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 97-103.	3.7	33
261	Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®. <i>Biologics: Targets and Therapy</i> , 2008, 2, 463.	3.2	16
262	The natural course of non-functioning pituitary macroadenomas. <i>European Journal of Endocrinology</i> , 2007, 156, 217-224.	3.7	175
263	Increased Daytime Somnolence despite Normal Sleep Patterns in Patients Treated for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3898-3903.	3.6	33
264	Bexarotene-Induced Hypothyroidism: Bexarotene Stimulates the Peripheral Metabolism of Thyroid Hormones. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2496-2499.	3.6	45
265	Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2610-2615.	3.6	136
266	Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation. <i>European Journal of Endocrinology</i> , 2007, 156, 155-165.	3.7	27
267	Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. <i>European Journal of Endocrinology</i> , 2007, 157, 709-716.	3.7	15
268	Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 976-981.	3.6	201
269	The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. <i>European Journal of Endocrinology</i> , 2007, 156, 455-462.	3.7	80
270	Quality of life is decreased in female patients treated for microprolactinoma. <i>European Journal of Endocrinology</i> , 2007, 157, 133-139.	3.7	48

#	ARTICLE	IF	CITATIONS
271	Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay. <i>Nuclear Medicine Communications</i> , 2007, 28, 123-127.	1.1	4
272	Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients. <i>Clinical Endocrinology</i> , 2007, 66, 070115055241003.	2.4	9
273	Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma. <i>Pituitary</i> , 2007, 10, 61-65.	2.9	53
274	Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. <i>Pituitary</i> , 2007, 10, 237-249.	2.9	50
275	Role of radiotherapy in the management of acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 449-460.	2.4	10
276	Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. <i>Growth Hormone and IGF Research</i> , 2006, 16, 101-107.	1.1	42
277	Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. <i>Clinical Endocrinology</i> , 2006, 64, 284-291.	2.4	63
278	A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease. <i>Clinical Endocrinology</i> , 2006, 64, 060222010233007.	2.4	8
279	Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. <i>Clinical Endocrinology</i> , 2006, 64, 617-624.	2.4	57
280	Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2006, 66, 061109020454001-???	2.4	83
281	Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 451-455.	2.4	9
282	Association of interferon- $\gamma$ and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2006, 145, 480-484.	2.6	31
283	Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2006, 154, 525-531.	3.7	54
284	Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3364-3369.	3.6	111
285	A Variable Degree of Intrauterine and Postnatal Growth Retardation in a Family with a Missense Mutation in the Insulin-Like Growth Factor I Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3062-3070.	3.6	132
286	Clinical and Biochemical Characteristics of a Male Patient with a Novel Homozygous STAT5b Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3482-3485.	3.6	87
287	Observation Alone after Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1796-1801.	3.6	195
288	GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. <i>European Journal of Endocrinology</i> , 2006, 154, 851-858.	3.7	20

#	ARTICLE	IF	CITATIONS
289	Quality of life in treated adult craniopharyngioma patients. European Journal of Endocrinology, 2006, 154, 483-489.	3.7	103
290	Survival and Death Causes in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 313-319.	3.6	248
291	Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. European Journal of Endocrinology, 2006, 155, 701-708.	3.7	43
292	Malignant prolactinoma: case report and review of the literature. European Journal of Endocrinology, 2006, 155, 523-534.	3.7	60
293	Nanomedicines in the treatment of acromegaly: focus on pegvisomant. International Journal of Nanomedicine, 2006, 1, 385-398.	6.7	21
294	High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clinical Endocrinology, 2005, 62, 197-204.	2.4	182
295	Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E63-E70.	3.5	9
296	Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. European Journal of Endocrinology, 2005, 152, 53-60.	3.7	23
297	Irregular and Frequent Cortisol Secretory Episodes with Preserved Diurnal Rhythmicity in Primary Adrenal Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1570-1577.	3.6	28
298	Effects of Dehydroepiandrosterone, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3295-3303.	3.6	61
299	Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2855-2864.	3.6	285
300	Reversible Diastolic Dysfunction after Long-Term Exogenous Subclinical Hyperthyroidism: A Randomized, Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6041-6047.	3.6	96
301	Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2731-2739.	3.6	182
302	Treatment strategies for acromegaly. Expert Opinion on Emerging Drugs, 2005, 10, 875-890.	2.4	12
303	Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. European Journal of Endocrinology, 2005, 153, 231-238.	3.7	24
304	Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormone and IGF Research, 2005, 15, 200-206.	1.1	32
305	Pharmacologic Therapies for Acromegaly. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 43-53.	1.8	24
306	Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3279-3286.	3.6	225

#	ARTICLE	IF	CITATIONS
307	Current pharmacotherapy for acromegaly: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 2393-2405.	1.8	24
308	Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E25-E30.	3.5	41
309	Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2789-2796.	3.6	188
310	Pituitary Magnetic Resonance Imaging Is Not Required in the Postoperative Follow-Up of Acromegalic Patients with Long-Term Biochemical Cure after Transsphenoidal Surgery. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4320-4324.	3.6	27
311	Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5369-5376.	3.6	213
312	Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 2004, 150, 489-495.	3.7	65
313	Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clinical Endocrinology, 2004, 60, 568-575.	2.4	49
314	Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease. Clinical Endocrinology, 2004, 60, 765-772.	2.4	26
315	Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clinical Endocrinology, 2004, 61, 61-74.	2.4	165
316	Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 71-75.	3.6	138
317	Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clinical Endocrinology, 2003, 58, 288-295.	2.4	42
318	Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology, 2003, 58, 428-435.	2.4	120
319	Outcome of Palliative Embolization of Bone Metastases in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3184-3189.	3.6	106
320	Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5858-5864.	3.6	161
321	Aminophylline stimulates insulin secretion in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2001, 50, 1030-1035.	3.4	14
322	Indomethacin Does Not Affect Endogenous Glucose Production in Type 2 Diabetes Mellitus. Hormone and Metabolic Research, 2001, 33, 659-663.	1.5	2
323	The Quantification of Gluconeogenesis in Healthy Men by 2H2O and [2-13C]Glycerol Yields Different Results: Rates of Gluconeogenesis in Healthy Men Measured with 2H2O Are Higher Than Those Measured with [2-13C]Glycerol. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2220-2226.	3.6	76
324	The Effects of Carbohydrate Variation in Isocaloric Diets on Glycogenolysis and Gluconeogenesis in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1963-1967.	3.6	44

#	ARTICLE	IF	CITATIONS
325	No Correlation between A(→1438)G Polymorphism in 5-HT2A Receptor Gene Promoter and the Density of Frontal Cortical 5-HT2A Receptors in Schizophrenia. Human Heredity, 1999, 49, 103-105.	0.8	63
326	5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet, The, 1997, 349, 1815.	13.7	40
327	Awareness & participation in rare disease registries within the European reference network on rare endocrine conditions (Endo-ERN). Endocrine Abstracts, 0, , .	0.0	0
328	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in mice. Endocrine Abstracts, 0, , .	0.0	0
329	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
330	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
331	Costs and Its Determinants in Pituitary Tumour Surgery. Frontiers in Endocrinology, 0, 13, .	3.5	1